The latest financial statement is for the year ending 2026-03-28.
| Cash Flow | 2026-03-28 |
|---|---|
| Net income | 97,308 |
| Depreciation and amortization | 111,717 |
| Amortization of fair value inventory step-up | 5,814 |
| Share-based compensation expense | 33,827 |
| Impairment of intangible assets | 86,546 |
| Gain on repurchase of convertible senior notes, net | 0 |
| Gains on sales of property, plant and equipment | 714 |
| Remeasurement of contingent consideration | -1,879 |
| Deferred income taxes | -26,471 |
| Other non-cash operating activities | 10,726 |
| Change in accounts receivable | 14,881 |
| Change in inventories | -47,361 |
| Change in prepaid income taxes | 4,534 |
| Change in other assets and other liabilities | 35,028 |
| Change in accounts payable and accrued expenses | -16,571 |
| Net cash provided by operating activities | 293,221 |
| Capital expenditures | 32,780 |
| Proceeds from divestiture and sale of assets | 0 |
| Proceeds from sale of property, plant and equipment | 1,375 |
| Non-cash transfers from inventory to property, plant and equipment for haemonetics equipment | -51,891 |
| Acquisitions | 60,180 |
| Other investments | 36,071 |
| Net cash used in investing activities | -179,547 |
| Proceeds from issuance of convertible notes | 0 |
| Repayment and repurchase of convertible notes | 300,000 |
| Purchase of capped call related to convertible notes | 0 |
| Term loan borrowings | 0 |
| Term loan redemption | 0 |
| Repayment of term loan borrowings | 6,250 |
| Proceeds from revolving facility | 300,000 |
| Payments on revolving facility | 0 |
| Debt issuance costs | 0 |
| Proceeds from employee stock purchase plan | 7,893 |
| Cash used to net share settle employee equity awards | 5,001 |
| Share repurchases | 175,000 |
| Other financing activities | -102 |
| Net cash (used in) provided by financing activities | -178,460 |
| Effect of exchange rates on cash and cash equivalents | 3,463 |
| Net change in cash and cash equivalents | -61,323 |
| Cash and cash equivalents at beginning of year | 306,763 |
| Cash and cash equivalents at end of year | 245,440 |
HAEMONETICS CORP (HAE)
HAEMONETICS CORP (HAE)